Cervical Cancer

    Actionable Target Abnormality Prevalence (1,2) Clinical Experience with Targeted Agent
    PIK3CA Mutation 37.5% (squamous cell)
    14%–25% (adenocarcinoma)
    Temsirolimus (mTOR inhibitor):
    • Phase 2: RR 3%, SD 58% (3)
    PTEN Protein loss 13% (squamous cell)
    3.6% (adenocarcinoma)
    VEGF-A Expression Associated with poorer prognosis (4) Bevacizumab (VEGF inhibitor):
    • Phase 2: RR 11%, SD 24% (5)
    • Retrospective analysis, with 5FU or capecitabine: RR 34%, SD 33% (6)
    • Phase 3, with cisplatin/paclitaxel or topotecan/paclitaxel: RR 48% (7)
    Sunitinib (VEGFR/PDGFR/RET/KIT/FLT3inhibitor):
    • Phase 2: RR 0%, SD 84% (8)
    Pazopanib (VEGFR inhibitor):
    • Phase 9%, SD 24% (9) Karp9781496389138-
    Other topics in Targets by Organ Site